Siemens Healthineers has received CE-Mark for its ultra-high-field 7T magnetic resonance (MR) scanner Magnetom Terra, making it available for neurological and musculoskeletal clinical examinations in Europe.
Cel-Sci said today that for a Phase III trial of its investigational immunotherapy, it inked an agreement with institutional investors for a $3.5 million registered direct offering.
The adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older has been cleared by the Medicines and Healthcare products Regulatory Agency.
FDA has cleared Irish life sciences company Malin Corp for its Hourglass peripheral embolization plug.
A five-year strategic research collaboration between AstraZeneca and its global biologics research and development arm MedImmune and Ethris, a company focussed on mRNA-based therapeutics with specific expertise in pulmonary disease.
The 13th Health Asia & Pharma Asia International Exhibition & Conferences (Pharma Asia) will be held at the Karachi Expo Center from August 22nd to August 24th 2017. As the leading global pharmaceutical and medical device B2B online platform, Ddu is going to attend the exhibition along with the products of high priority members.
MyoVista hsECG testing device has been developed for front-line screening of cardiac disease in both symptomatic and asymptomatic patients.
A press conference for the launch of the Ddu Credit Verification service was successfully held at Shenzhenair International Hotel, HallⅠin Shenzhen, China on August 18, 2017.
NeoSync has announced the completion of its Series D financing round, which included investment from Valiance Life Science Investments, as well as its original investor base totaling $13m.
Being set to supply ingredients for around 400 million vaccines a year, a new £44 million aluminium salts facilityhas been officially opened by GlaxoSmithKline in Montrose, Scotland.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.